References
- Bartalesi F, Spinicci M, Mencarini J, et al. The role of Quantiferon-TB Gold in-Tube in the diagnosis and treatment monitoring of active tuberculosis. Infect Dis (Lond). 2017;49:474–477.
- Tagmouti S, Slater M, Benedetti A, et al. Reproducibility of interferon gamma (IFN-gamma) release assays. A systematic review. Annals Ats. 2014;11:1267–1276.
- Joshi M, Monson TP, Joshi A, et al. IFN-gamma release assay conversions and reversions. Challenges with serial testing in U.S. health care workers. Annals Ats. 2014;11:296–302.
- Banaei N, Gaur RL, Pai M. Interferon gamma release assays for latent tuberculosis: what are the sources of variability? J Clin Microbiol. 2016;54:845–850.
- Detjen AK, Loebenberg L, Grewal HM, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol. 2009;16:1170–1175.
- Ewer K, Millington KA, Deeks JJ, et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006;174:831–839.
- Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis. 2009;13:84–92.
- King TC, Upfal M, Gottlieb A, et al. T-SPOT.TB interferon-gamma release assay performance in healthcare worker screening at Nineteen U.S. hospitals. Am J Respir Crit Care Med. 2015;192:367–373.
- Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185:427–434.
- Mazurek GH, Jereb JA, Vernon A, et al. Committee IE, Control CfD, Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection, United States, 2010: Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.